Select Page

Brad Verret

Brad Verret was biochemist and former medical student who was employed at The Dow Chemical Company in polymer characterization. He served on our general advisory board. Brad’s benzodiazepine injury from Xanax began in 2011 as an undergraduate student. His health began to decline and he developed neurological symptoms consistent with multiple sclerosis. In 2014, Brad became aware of his benzodiazepine dependence the resulting harm to his health, leading to being rapidly tapered off the drug in a week. After suffering four agonizing months from the rapid withdrawal, he was reinstated and slowly tapered off Valium for a year, which was completed in August 2016. Brad enjoyed using his free time to share his experience, strength, and hope with those impacted by iatrogenic illness. Brad passed away in 2017.

 

 

 

 

 

 

 

Hidden Dangers of Fluoroquinolone Antibiotics in the Benzodiazepine-Dependent Population
Whether it was for a sinus infection or bronchitis, most people have taken an antibiotic at some point in their ...
Read More

Hidden Dangers of Fluoroquinolone Antibiotics in the Benzodiazepine-Dependent Population

Psychopharmacology and Commonly Encountered Enzymatic Drug-Drug Interactions: Implications on Psychiatric Treatment and Psychopharmaceutical Discontinuation Protocols
It’s no surprise that drugs don’t always play together nicely in the human body. The term “drug interaction” can stir ...
Read More

Psychopharmacology and Commonly Encountered Enzymatic Drug-Drug Interactions: Implications on Psychiatric Treatment and Psychopharmaceutical Discontinuation Protocols

Share This